Comparing the efficacy of α-glucosidase inhibitors in suppressing postprandial hyperglycemia using continuous glucose monitoring: A pilot study - The MAJOR study

Diabetes Technology and Therapeutics

Volumn 13, Issue 3, 2011, Pages 303-308

  Tsujino, Daisuke ^a   Nishimura, Rimei ^a,b   Taki, Kentaro ^a   Morimoto, Aya ^a   Tajima, Naoko ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCOSE; HEMOGLOBIN A1C; MIGLITOL; VOGLIBOSE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; FEMALE; GLYCEMIC INDEX; HUMAN; HYPERGLYCEMIA; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; PILOT STUDY; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

1-DEOXYNOJIRIMYCIN; ACARBOSE; ADULT; AGED; ALPHA-GLUCOSIDASES; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; FEMALE; HUMANS; HYPERGLYCEMIA; JAPAN; MALE; MIDDLE AGED; PILOT PROJECTS; YOUNG ADULT;

EID: 79952173246     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2010.0099     Document Type: Article

References (19)

1. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999;354:617-621.
2. Nakagami T; DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004;47: 385-394. (Pubitemid 38491233)
3. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583. (Pubitemid 26397370)
4. NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaciong Z, Gaztambide S, Giles T, Horton E, Ilkova H, Jenssen T, Kahn SE, Krum H, Laakso M, Leiter LA, Levitt NS, Mareev V, Martinez F, Masson C, Mazzone T, Meaney E, Nesto R, Pan C, Prager R, Raptis SA, Rutten GE, Sandstroem H, Schaper F, Scheen A, Schmitz O, Sinay I, Soska V, Stender S, Tamás G, Tognoni G, Tuomilehto J, Villamil AS, Vozá r J, Califf RM: Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med 2010;362:1463-1476. Erratum in N Engl J Med 2010;362;1748.
5. Guideline for Management of Postmeal Glucose. www.idf.org/webdata/docs/ Guideline-PMG-final.pdf (accessed May 19, 2010).
6. American Diabetes Association: Standards of medical care in diabetes-2009. Diabetes Care 2009;32(Suppl 1):S13-S61.
7. Esposito K, Ciotola M, Carleo D, Schisano B, Sardelli L, Di Tommaso D, Misso L, Saccomanno F, Ceriello A, Giugliano D: Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008;93:1345-1350. (Pubitemid 351519731)
8. Tsujino D, Nishimura R, Taki K, Miyashita Y, Morimoto A, Tajima N: Daily glucose profiles in Japanese people with normal glucose tolerance as assessed by continuous glucose monitoring. Diabetes Technol Ther 2009;11:457-460.
9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072-2077. (Pubitemid 34680970)
10. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; Voglibose Ph-3 Study Group: Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-1614.
11. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W: Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 1997;47:734-745.
12. Yoshino G, Tominaga M, Hirano T, Shiba T, Kashiwagi A, Tanaka A, Tada N, Onuma T, Egusa G, Kuwashima, Sanke T, Oikawa S, Honda K, Tachikawa T: The test meal A: a pilot model for the international standard of test meal for an assessment of both postprandial hyperglycemia and hyperlipidemia. J Jpn Diabetes Soc 2006;49:361-371. (Pubitemid 43973939)
13. Cheyne EH, Cavan DA, Kerr D: Performance of a continuous glucose monitoring system during controlled hypoglycaemia in healthy volunteers. Diabetes Technol Ther 2002;4: 607-613. (Pubitemid 35283323)
14. Boyne MS, Silver DM, Kaplan J, Saudek CD: Timing of changes in interstitial and venous blood glucose measured with a continuous subcutaneous glucose sensor. Diabetes 2003;52:2790-2794. (Pubitemid 37339709)
15. National Health and Nutrition Survey in Japan-2009. www.mhlw.go.jp/ houdou/2009/11/h1109-1.html (accessed May 19, 2010).
16. Shiwaku K, Hashimoto M, Nogi A, Kitajima K, Yamasaki M: Traditional Japanese dietary basics: a solution for modern health issues? Lancet 2004;363:1737-1738. (Pubitemid 38670340)
17. Arakawa M, Ebato C, Mita T, Fujitani Y, Shimizu T, Watada H, Kawamori R, Hirose T: Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon- like peptide 1 secretion in viscerally obese subjects. Metabolism 2008;57:1299-1306.
18. Van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005;28:154-163. (Pubitemid 40095800)
19. Yokoyama H, Kannno S, Ishimura I, Node K: Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. Metabolism 2007;56:1458-1463. (Pubitemid 47562494)